Animal models of myasthenia gravis: utility and limitations

References

• LindstromJMSeyboldMELennonVAAntibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic valueNeurology19762610541059988512
   PubMed Web of Science ®Google Scholar
• TrotterJLRingelSPCookJDMorphologic and immunologic studies in experimental autoimmune myasthenia gravis and myasthenia gravisNeurology1977271120112473154
   PubMed Web of Science ®Google Scholar
• MeriggioliMNMyasthenia gravis with anti-acetylcholine receptor antibodiesFront Neurol Neurosci2009269410819349707
   PubMedGoogle Scholar
• TzartosSJMorelEEfthimiadisAFine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravisClin Exp Immunol19887480862464451
   PubMed Web of Science ®Google Scholar
• Newsom-DavisJWillcoxNCalderLThymus cells in myasthenia gravis selectively enhance production of anti-acetylcholine-receptor antibody by autologous blood lymphocytesN Engl J Med1981305131313187290153
   PubMed Web of Science ®Google Scholar
• MelmsALutherCStoeckleCThymus and myasthenia gravis: antigen processing in the human thymus and the consequences for the generation of autoreactive T cellsActa Neurol Scand Suppl2006183121316637920
   PubMedGoogle Scholar
• CavalcantePLe PanseRBerrih-AkninSThe thymus in myasthenia gravis: site of “innate autoimmunity”?Muscle Nerve20114446748421922466
   PubMed Web of Science ®Google Scholar
• HoedemaekersACvan Breda VriesmanPJDe BaetsMHMyasthenia gravis as a prototype autoimmune receptor diseaseImmunol Res1997163413549439759
   PubMed Web of Science ®Google Scholar
• VincentALeiteMIFarrugiaMEMyasthenia gravis seronegative for acetylcholine receptor antibodiesAnn N Y Acad Sci20081132849218567857
   PubMed Web of Science ®Google Scholar
• CordiglieriCMaroldaRFranziSInnate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunityJ Autoimmun201452748924397961
   PubMed Web of Science ®Google Scholar
• DrachmanDBAutonomic “myasthenia”: the case for an autoimmune pathogenesisJ Clin Invest200311179779912639983
   PubMed Web of Science ®Google Scholar
• VincentAUnravelling the pathogenesis of myasthenia gravisNat Rev Immunol2002279780412360217
   PubMed Web of Science ®Google Scholar
• VincentADrachmanDBMyasthenia gravisAdv Neurol20028815918811908224
   PubMedGoogle Scholar
• EngelAGLambertEHHowardFMImmune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlationsMayo Clin Proc197752267280870771
   PubMed Web of Science ®Google Scholar
• ToykaKVBrachmanDBPestronkAMyasthenia gravis: passive transfer from man to mouseScience19751903973991179220
   PubMed Web of Science ®Google Scholar
• FuchsSArichaRReuveniDExperimental autoimmune myasthenia gravis (EAMG): from immunochemical characterization to therapeutic approachesJ Autoimmun201454515924970384
   PubMed Web of Science ®Google Scholar
• PatrickJLindstromJCulpBStudies on purified eel acetylcholine receptor and anti-acetylcholine receptor antibodyProc Natl Acad Sci U S A197370333433384128544
   PubMed Web of Science ®Google Scholar
• DauPCPlasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patientsArch Neurol1981385445527271533
   PubMedGoogle Scholar
• AntozziCGemmaMRegiBA short plasma exchange protocol is effective in severe myasthenia gravisJ Neurol19912381031071856735
   PubMed Web of Science ®Google Scholar
• Conti-FineBMMilaniMKaminskiHJMyasthenia gravis: past, present, and futureJ Clin Invest20061162843285417080188
   PubMed Web of Science ®Google Scholar
• EngelAGFumagalliGMechanisms of acetylcholine receptor loss from the neuromuscular junctionCiba Found Symp1982901972246923808
   PubMedGoogle Scholar
• GomezCMRichmanDPAnti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myastheniaProc Natl Acad Sci U S A198380408940936575398
   PubMed Web of Science ®Google Scholar
• BaggiFAntozziCToscaniCAcetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?Arch Immunol Ther Exp (Warsz)201260193022159475
   PubMed Web of Science ®Google Scholar
• ChristadossPPoussinMDengCAnimal models of myasthenia gravisClin Immunol200094758710637092
   PubMed Web of Science ®Google Scholar
• LinkHXiaoBGRat models as tool to develop new immunotherapiesImmunol Rev200118411712811918681
   PubMed Web of Science ®Google Scholar
• BaggiFAnnoniAUbialiFBreakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in ratsJ Immunol20041722697270314764745
   PubMed Web of Science ®Google Scholar
• BaggiFAnnoniAUbialiFImmunization with rat-, but not Torpedo-derived 97-116 peptide of the AChR alpha-subunit induces experimental myasthenia gravis in Lewis ratAnn N Y Acad Sci200399839139414592903
   PubMed Web of Science ®Google Scholar
• BermanPWPatrickJExperimental myasthenia gravis. A murine systemJ Exp Med19801512042237350247
   PubMed Web of Science ®Google Scholar
• BermanPWPatrickJLinkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravisJ Exp Med19801525075206774045
   PubMed Web of Science ®Google Scholar
• LindstromJExperimental autoimmune myasthenia gravisJ Neurol Neurosurg Psychiatry1980435685766249892
   PubMed Web of Science ®Google Scholar
• BieseckerGGomezCMInhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6J Immunol1989142265426592703710
   PubMed Web of Science ®Google Scholar
• XieXMuLYaoXATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh/Tfr helper cell profilesClin Immunol201314816217623773919
   PubMed Web of Science ®Google Scholar
• WangCCLiHZhangMCaspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathwayJ Neuroinflammation20151211826071315
   PubMed Web of Science ®Google Scholar
• LiNMuLWangJActivation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severityEur J Immunol2012421140115122539289
   PubMed Web of Science ®Google Scholar
• LiNWangGYaoXAdenosine receptor expression in a rat model of experimental autoimmune myasthenia gravisCell Immunol201429021722525086239
   PubMed Web of Science ®Google Scholar
• TzartosSHochschwenderSVasquezPPassive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptorJ Neuroimmunol1987151851943495549
   PubMed Web of Science ®Google Scholar
• PiddlesdenSJJiangSLevinJLSoluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravisJ Neuroimmunol1996711731778982117
   PubMed Web of Science ®Google Scholar
• KusnerLLLosenMVincentAGuidelines for pre-clinical assessment of the acetylcholine receptor – specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designsExp Neurol201527031025743217
   PubMed Web of Science ®Google Scholar
• SchonbeckSPadbergFHohlfeldRTransplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravisJ Clin Invest1992902452501634612
   PubMed Web of Science ®Google Scholar
• WangZYKarachunskiPIHowardJFJrMyasthenia in SCID mice grafted with myasthenic patient lymphocytes: role of CD4+ and CD8+ cellsNeurology19995248449710025776
   PubMed Web of Science ®Google Scholar
• MartinoGDuPontBLWollmannRLThe human-severe combined immunodeficiency myasthenic mouse model: a new approach for the study of myasthenia gravisAnn Neurol19933448568517679
   PubMed Web of Science ®Google Scholar
• HochWMcConvilleJHelmsSAuto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodiesNat Med2001736536811231638
   PubMed Web of Science ®Google Scholar
• McConvilleJVincentADiseases of the neuromuscular junctionCurr Opin Pharmacol2002229630112020474
   PubMed Web of Science ®Google Scholar
• OhtaRMotomuraMAutoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravisRinsho Byori20146225526024800501
   PubMedGoogle Scholar
• GhazanfariNFernandezKJMurataYMuscle specific kinase: organiser of synaptic membrane domainsInt J Biochem Cell Biol20114329529820974278
   PubMed Web of Science ®Google Scholar
• JhaSXuKMarutaTMyasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK)J Neuroimmunol200617510711716697051
   PubMed Web of Science ®Google Scholar
• PhillipsWDChristadossPLosenMGuidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravisExp Neurol2015270294025542979
   PubMed Web of Science ®Google Scholar
• BanJPhillipsWDMouse models of myasthenia gravisCurr Pharm Des2015212468248625777761
   PubMed Web of Science ®Google Scholar
• UlusoyCKimETuzunEPreferential production of IgG1, IL-4 and IL-10 in MuSK-immunized miceClin Immunol201415115516324589747
   PubMed Web of Science ®Google Scholar
• ColeRNReddelSWGervasioOLAnti-MuSK patient antibodies disrupt the mouse neuromuscular junctionAnn Neurol20086378278918384168
   PubMed Web of Science ®Google Scholar
• ColeRNGhazanfariNNgoSTPatient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in miceJ Physiol20105883217322920603331
   PubMed Web of Science ®Google Scholar
• MorschMReddelSWGhazanfariNPyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibodyJ Physiol20135912747276223440963
   PubMed Web of Science ®Google Scholar
• MorschMReddelSWGhazanfariNMuscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptorsExp Neurol201223728629522789393
   PubMed Web of Science ®Google Scholar
• PevznerASchoserBPetersKAnti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravisJ Neurol201225942743521814823
   PubMed Web of Science ®Google Scholar
• ZhangBTzartosJSBelimeziMAutoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravisArch Neurol20126944545122158716
   PubMed Web of Science ®Google Scholar
• ZongYZhangBGuSStructural basis of agrin-LRP4-MuSK signalingGenes Dev20122624725822302937
   PubMed Web of Science ®Google Scholar
• HiguchiOHamuroJMotomuraMAutoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravisAnn Neurol20116941842221387385
   PubMed Web of Science ®Google Scholar
• MotomuraMHiguchiOProgress of myasthenia gravis: discovery of Lrp4 antibodiesRinsho Shinkeigaku2012521303130523196599
   PubMedGoogle Scholar
• BarikALuYSathyamurthyALRP4 is critical for neuromuscular junction maintenanceJ Neurosci201434138921390525319686
   PubMed Web of Science ®Google Scholar
• ShenCLuYZhangBAntibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravisJ Clin Invest20131235190520224200689
   PubMed Web of Science ®Google Scholar
• CavalcantePCufiPMantegazzaREtiology of myasthenia gravis: innate immunity signature in pathological thymusAutoimmun Rev20131286387423535157
   PubMed Web of Science ®Google Scholar
• MuLSunBKongQDisequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravisImmunology2009128e826e83619740344
   PubMed Web of Science ®Google Scholar
• SchaffertHPelzASaxenaAIL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravisEur J Immunol2015451339134725676041
   PubMed Web of Science ®Google Scholar
• BarchanDSouroujonMCImSHAntigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunitProc Natl Acad Sci U S A1999968086809110393952
   PubMed Web of Science ®Google Scholar
• ImSHBarchanDFuchsSSuppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragmentJ Clin Invest19991041723173010606626
   PubMed Web of Science ®Google Scholar
• MaitiPKFefermanTImSHImmunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragmentJ Neuroimmunol200415211212015223243
   PubMed Web of Science ®Google Scholar
• OkumuraSMcIntoshKDrachmanDBOral administration of acetylcholine receptor: effects on experimental myasthenia gravisAnn Neurol1994367047137979216
   PubMed Web of Science ®Google Scholar
• BaggiFAndreettaFCaspaniEOral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravisJ Clin Invest19991041287129510545527
   PubMed Web of Science ®Google Scholar
• BanchereauJSteinmanRMDendritic cells and the control of immunityNature19983922452529521319
   PubMed Web of Science ®Google Scholar
• JonuleitHSchmittESteinbrinkKDendritic cells as a tool to induce anergic and regulatory T cellsTrends Immunol20012239440011429324
   PubMed Web of Science ®Google Scholar
• KruegerTWohlrabUKluckenMAutoantigen-specific protection of non-obese diabetic mice from cyclophosphamide-accelerated diabetes by vaccination with dendritic cellsDiabetologia2003461357136512928772
   PubMed Web of Science ®Google Scholar
• RoncaroloMGLevingsMKTraversariCDifferentiation of T regulatory cells by immature dendritic cellsJ Exp Med2001193F5F911208869
   PubMed Web of Science ®Google Scholar
• YarilinDDuanRHuangYMDendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravisClin Exp Immunol200212721421911876742
   PubMed Web of Science ®Google Scholar
• DuanRSAdikariSBHuangYMProtective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cellsNeurobiol Dis20041646146715193302
   PubMed Web of Science ®Google Scholar
• XiaoBGDuanRSLinkHInduction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cellsCell Immunol2003223636912914759
   PubMed Web of Science ®Google Scholar
• XiaoBGHuangYMLinkHDendritic cell vaccine design: strategies for eliciting peripheral tolerance as therapy of autoimmune diseasesBioDrugs20031710311112641489
   PubMed Web of Science ®Google Scholar
• LiLSunSCaoXExperimental study on induction of tolerance to experimental autoimmune myasthenia gravis by immature dendritic cellsJ Huazhong Univ Sci Technolog Med Sci20052521521816116977
   PubMedGoogle Scholar
• ShengJRLiLGaneshBBSuppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cellsJ Immunol20061775296530617015715
   PubMed Web of Science ®Google Scholar
• AdamsonPGreenwoodJHow do statins control neuroinflammation?Inflamm Res20035239940314520514
   PubMed Web of Science ®Google Scholar
• GreenwoodJWaltersCEPryceGLovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitisFASEB J20031790590712626426
   PubMed Web of Science ®Google Scholar
• LiXLLiuYCaoLLAtorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokinesMol Cell Neurosci201356859523541702
   PubMed Web of Science ®Google Scholar
• LiHWangCCZhangMStatin-modified dendritic cells regulate humoral immunity in experimental autoimmune myasthenia gravisMol Cell Neurosci20156828429226311508
   PubMed Web of Science ®Google Scholar
• ZhangYYangHXiaoBEffect of RelB-silenced BMDC pulsed with Talpha146~162 on immunoreaction of T cells primed with TAChRZhong Nan Da Xue Xue Bao Yi Xue Ban201035384420130363
   PubMedGoogle Scholar
• SunWAdamsRNMiagkovASpecific immunotherapy of experimental myasthenia gravis in vitro and in vivo: the Guided Missile strategyJ Neuroimmunol2012251253222769060
   PubMed Web of Science ®Google Scholar
• BuNWuHQZhangGLImmature dendritic cell exosomes suppress experimental autoimmune myasthenia gravisJ Neuroimmunol2015285717526198922
   PubMed Web of Science ®Google Scholar
• FehervariZSakaguchiSControl of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cellsInt Immunol2004161769178015520045
   PubMed Web of Science ®Google Scholar
• PiccirilloCAd’HennezelESgouroudisECD4+Foxp3+ regulatory T cells in the control of autoimmunity: in vivo veritasCurr Opin Immunol20082065566218926906
   PubMed Web of Science ®Google Scholar
• SakaguchiSNaturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responsesAnnu Rev Immunol20042253156215032588
   PubMed Web of Science ®Google Scholar
• BattagliaADi SchinoCFattorossiACirculating CD4+CD25+ T regulatory and natural killer T cells in patients with myasthenia gravis: a flow cytometry studyJ Biol Regul Homeost Agents200519546216178275
   PubMed Web of Science ®Google Scholar
• FattorossiABattagliaABuzzonettiACirculating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatmentImmunology200511613414116108825
   PubMed Web of Science ®Google Scholar
• MatsuiNNakaneSSaitoFUndiminished regulatory T cells in the thymus of patients with myasthenia gravisNeurology20107481682020211905
   PubMed Web of Science ®Google Scholar
• BalandinaALecartSDartevellePFunctional defect of regulatory CD4 (+) CD25+ T cells in the thymus of patients with autoimmune myasthenia gravisBlood200510573574115454488
   PubMed Web of Science ®Google Scholar
• ArichaRFefermanTFuchsSEx vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravisJ Immunol20081802132213918250419
   PubMed Web of Science ®Google Scholar
• NessiVNavaSRuoccoCNaturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravisJ Immunol20101855656566720881192
   PubMed Web of Science ®Google Scholar
• YoungMRAquinoSYoungMEDifferential induction of hematopoiesis and immune suppressor cells in the bone marrow versus in the spleen by Lewis lung carcinoma variantsJ Leukoc Biol1989452622732522492
   PubMed Web of Science ®Google Scholar
• HansonEMClementsVKSinhaPMyeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cellsJ Immunol200918393794419553533
   PubMed Web of Science ®Google Scholar
• Ostrand-RosenbergSSinhaPMyeloid-derived suppressor cells: linking inflammation and cancerJ Immunol20091824499450619342621
   PubMed Web of Science ®Google Scholar
• LiYTuZQianSMyeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravisJ Immunol20141932127213425057008
   PubMed Web of Science ®Google Scholar
• KongQFSunBBaiSSAdministration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-betaJ Neuroimmunol2009207839119174310
   PubMed Web of Science ®Google Scholar
• KongQFSunBWangGYBM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDOEur J Immunol20093980080919283707
   PubMed Web of Science ®Google Scholar
• ShengJRQuanSSolivenBCD1d(hi)CD5+ B cells expanded by GM-CSF in vivo suppress experimental autoimmune myasthenia gravisJ Immunol20141932669267725135828
   PubMed Web of Science ®Google Scholar
• ImSHBarchanDMaitiPKBlockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4J Immunol20011666893689811359850
   PubMed Web of Science ®Google Scholar
• ArichaRMizrachiKFuchsSBlocking of IL-6 suppresses experimental autoimmune myasthenia gravisJ Autoimmun20113613514121193288
   PubMed Web of Science ®Google Scholar
• FefermanTArichaRMizrachiKSuppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3J Neuroimmunol2009209879519232748
   PubMed Web of Science ®Google Scholar
• FefermanTMaitiPKBerrih-AkninSOverexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravisJ Immunol20051745324533115843529
   PubMed Web of Science ®Google Scholar
• YaoXKongQXieXNeutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responsesImmunology201414339640524850614
   PubMed Web of Science ®Google Scholar
• ShiFDTakedaKAkiraSIL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cellsJ Immunol20001653099310410975822
   PubMed Web of Science ®Google Scholar
• ImSHBarchanDMaitiPKSuppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18FASEB J2001152140214811641240
   PubMed Web of Science ®Google Scholar
• LiuRZhouQLa CavaAExpansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myastheniaEur J Immunol2010401577158920352624
   PubMed Web of Science ®Google Scholar
• ChaeCSKwonHKHwangJSProphylactic effect of probiotics on the development of experimental autoimmune myasthenia gravisPLoS One20127e5211923284891
   PubMed Web of Science ®Google Scholar
• MantegazzaRBonannoSCameraGCurrent and emerging therapies for the treatment of myasthenia gravisNeuropsychiatr Dis Treat2011715116021552317
   PubMed Web of Science ®Google Scholar
• GomezAMVrolixKMartinez-MartinezPProteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravisJ Immunol20111862503251321239719
   PubMed Web of Science ®Google Scholar
• UbialiFNavaSNessiVPixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis ratsJ Immunol20081802696270318250482
   PubMed Web of Science ®Google Scholar
• MaroldaRRuoccoCCordiglieriCDifferential targeting of immune-cells by pixantrone in experimental myasthenia gravisJ Neuroimmunol2013258415023523328
   PubMed Web of Science ®Google Scholar
• TuzunEChristadossPComplement associated pathogenic mechanisms in myasthenia gravisAutoimmun Rev20131290491123537510
   PubMed Web of Science ®Google Scholar
• Chamberlain-BanoubJNealJWMizunoMComplement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis ratsClin Exp Immunol200614627828617034580
   PubMed Web of Science ®Google Scholar
• MorganBPChamberlain-BanoubJNealJWThe membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in miceClin Exp Immunol200614629430217034582
   PubMed Web of Science ®Google Scholar
• LennonVASeyboldMELindstromJMRole of complement in the pathogenesis of experimental autoimmune myasthenia gravisJ Exp Med1978147973983206648
   PubMed Web of Science ®Google Scholar
• ChristadossPC5 gene influences the development of murine myasthenia gravisJ Immunol1988140258925923356901
   PubMed Web of Science ®Google Scholar
• KaminskiHJKusnerLLRichmondsCDeficiency of decay accelerating factor and CD59 leads to crisis in experimental myastheniaExp Neurol200620228729316859686
   PubMed Web of Science ®Google Scholar
• LinFKaminskiHJConti-FineBMMarkedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protectionJ Clin Invest20021101269127412417565
   PubMed Web of Science ®Google Scholar
• HudaRTuzunEChristadossPTargeting complement system to treat myasthenia gravisRev Neurosci20142557558324731953
   PubMed Web of Science ®Google Scholar
• SunLXingLZhangGHA new method to induce myasthenia gravis models and the protective effect of soluble decay accelerating factorsGenet Mol Res2015147782779226214459
   PubMed Web of Science ®Google Scholar
• SoltysJKusnerLLYoungANovel complement inhibitor limits severity of experimentally myasthenia gravisAnn Neurol200965677519194881
   PubMed Web of Science ®Google Scholar
• LosenMStassenMHMartinez-MartinezPIncreased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravisBrain20051282327233716150851
   PubMed Web of Science ®Google Scholar
• Martinez-MartinezPLosenMDuimelHOverexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravisAm J Pathol200717064465717255332
   PubMed Web of Science ®Google Scholar
• O’ConnellRMBaltimoreDMicroRNAs and hematopoietic cell developmentCurr Top Dev Biol20129914517422365738
   PubMed Web of Science ®Google Scholar
• ZhangJJiaGLiuQSilencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravisImmunology2015144566724962817
   PubMed Web of Science ®Google Scholar
• WangYZTianFFYanMDelivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravisClin Exp Immunol201417620722124387321
   PubMed Web of Science ®Google Scholar
• WangJZhengSXinNIdentification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell responseJ Neuroimmune Pharmacol201381287130224043548
   PubMed Web of Science ®Google Scholar
• LosenMMartinez-MartinezPMolenaarPCStandardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors – recommendations for methods and experimental designsExp Neurol2015270182825796590
   PubMed Web of Science ®Google Scholar
• TuzunEBerrih-AkninSBrennerTGuidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunizationExp Neurol2015270111725697844
   PubMed Web of Science ®Google Scholar
• CavalcantePBernasconiPMantegazzaRAutoimmune mechanisms in myasthenia gravisCurr Opin Neurol20122562162922941261
   PubMed Web of Science ®Google Scholar
• MelmsASchalkeBCKirchnerTThymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patientsJ Clin Invest1988819029082449461
   PubMed Web of Science ®Google Scholar
• MeinlEKlinkertWEWekerleHThe thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis ratAm J Pathol199113999510081951638
   PubMed Web of Science ®Google Scholar
• GomezAMWillcoxNVrolixKProteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patientsJ Immunol20141931055106324973445
   PubMed Web of Science ®Google Scholar
• RusselWMSBurchRLThe Principles of Humane Experimental TechniqueSpecial Edition UFAWLondonMethuen & Co1992
   Google Scholar
• MaCGZhangGXXiaoBGLinkJOlssonTLinkHSuppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptorJ Neuroimmunol199558151607537280
   PubMed Web of Science ®Google Scholar
• ZhangJMJiaGLiuQSilencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravisImmunology2014144566724962817
   PubMed Web of Science ®Google Scholar